A psychiatric medication system in the guise of a pill with a built-in digital tracking device procured approval from the US Food and Drug Administration. Abilify MyCite, a form of aripiprazole and a first-of-its-kind product, has an ingestible implanted sensor that documents when the medication is taken. Produced by Japan-based Otsuka Pharmaceutical Co, the medication structure is deliberated to cure schizophrenia, bipolar I disorder and depression in adults. Abilify in the absence of sensor technology was first endorsed to cure schizophrenia in 2002.
Schizophrenia, a psychotic disorder, involves indication misapprehensions and figment of imagination. Bipolar patients may face interspersed interludes of mania and depression, a persistent sadness. Even though the idea following Abilify MyCite is to ameliorate a patient’s agreement with their medicine guidance, the FDA noted that there was no evidence found for this.
Teens and young adults who are consuming antidepressants are at a higher rate of risk of suicidal tendency and notion when consuming medication alerts the box warning. They should be supervised meticulously. Well-being and efficacy has not been bestowed in children. Abilify MyCite is also not endorsed to cure aged patients with dementia-related psychosis.
The Abilify MyCite system dispatches a message from the pill’s sensor, which the organization introduced to as an “ingestible event marker,” to a patch worn on the patient’s skin. This sensor is the measures to a grain of sand and is composed of components found in food according to Otsuka. When the sensor corresponds to liquid in stomach and transmits to MyCite Patch, the sensor is assimilated and discarded from the body.